We establish the inferential properties of the mean-difference estimator for the average treatment effect in randomized experiments where each unit in a population of interest is randomized to one of two treatments and then units within treatment groups are randomly sampled. The properties of this estimator are well-understood in the experimental design scenario where first units are randomly sampled and then treatment is randomly assigned, but this is not the case for the aforementioned scenario where the sampling and treatment assignment stages are reversed. We find that the mean-difference estimator under this experimental design scenario is more precise than under the sample-first-randomize-second design, but only when there is treatment effect heterogeneity in the population. We also explore to what extent pre-treatment measurements can be used to improve upon the mean-difference estimator for this experimental design.
Introduction
In most typical two-armed randomized experiments conducted to compare the causal effects of two treatments (or one treatment and one control), a finite population of N experimental units is considered. These N units receive one of the treatments through a randomized assignment mechanism, and the observed outcomes from the two treatment groups are compared to draw * We would like to thank Marielle Remillard and Chad Vecitis for conversations and collaborative work that originally inspired this work. This research was supported by the National Science Foundation under Grant No. 1144152 and Grant No. DMS 1612901. Any opinions, findings,and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the National Science Foundation. inference on the causal estimands of interest. Such causal estimands can be defined in terms of potential outcomes, and the framework for drawing inference in the setup described above is the well-known Neyman-Rubin causal model (Sekhon 2008) or simply the Rubin causal model (Holland 1986 ). The most common estimand of interest is the average treatment effect (ATE). In a finite population setup where the potential outcomes are assumed fixed, the ATE is unbiasedly estimated by the difference of the average observed responses of units in the two treatment groups. The sampling variance of this estimator was derived by Neyman (1923) . To draw inference on the ATE, a normal approximation of its estimator is used. An implicit assumption necessary to implement this widely used inferential procedure is that, for each experimental unit, the response is observed for one of the treatments but missing for the other.
In many practical situations, it may not be possible to observe a response for all N units due to resource constraints. A natural way to address this limitation is to first randomly sample n units from the population and then randomly assign the two treatments to the sampled units. The difference of the average observed response in the two treatment groups still serves as an unbiased estimator of the ATE. This scenario (shown in the left panel of Figure 1 ) is described in Imbens and Rubin (2015, Pages 109-112) , where the sampling properties of the estimator of the ATE are derived.
The work in this article is motivated by a similar limitation as stated in the previous paragraph, but the experimental design is different in the sense that the order of sampling and randomization is reversed. That is, first, each of the N units is assigned to one of the two treatments. Then, a subset of units is sampled from the units exposed to each treatment group, and the response is measured for each sampled unit. This experimental design scenario is shown in the right panel of Figure 1 . Such a strategy may be useful if sampling and measurement of response is more expensive and/or complex compared to treatment assignment. Examples of experiments that involve this type of design can be found in material science, biomedicine, and the social sciences.
For example, in an experiment conducted to assess the difference between two types of oxidation procedures with respect to their impact on the dimension of nanotubes, scientists typically split a population (a container of nanotubes) into two subpopulations (two smaller containers) and apply different oxidation procedures to the two subpopulations (Remillard et al. 2016 (Remillard et al. , 2017 . However, since measuring dimensions of nanotubes is an expensive and time-consuming process, a sample of oxidized nanotubes is taken from each subpopulation, and dimensions of the sampled nanotubes are measured. A similar procedure is followed when conducting stem cell experiments (Chung et al. 2005; Doi et al. 2009 ). Design 2 is also similar-but not identical-to a cluster randomized controlled trial (Campbell et al. 2007 ), where one cluster of size N 1 is assigned to treatment group 1 and another cluster of size N 0 is assigned to treatment group 0, and random samples are obtained within each cluster. Cluster randomized controlled trials are quite common in education (Hedges and Hedberg 2007) , medicine (Eldridge et al. 2004) , and psychology (Raudenbush 1997 ).
The inference procedure for Design 1 is well understood and documented, but the case for Design 2 is not so obvious. In this article, we explore the sampling properties of the unbiased estimator of the ATE for Design 2 and compare them with those of Design 1. We also consider the case where baseline (pre-treatment) measurements of the response can be obtained for a sample of experimental units, and explore whether the natural estimator of the ATE can be improved by using such measurements.
Setup and Notations
Let the two treatments be denoted by 0 and 1, and for i = 1, . . . , N , let (Y i (0), Y i (1)) denote the potential outcomes for unit i when exposed to treatments 0 and 1, respectively. The unit-level treatment effect is
and the ATE is
denote the average potential outcomes for the treatment groups 1 and 0, respectively. We also denote the variances of the potential outcomes for treatment group T ∈ {0, 1} as follows:
and the covariance of potential outcomes for treatment groups 1 and 0 by
Finally, the variance of the unit-level treatment effects is
As in Design 2 shown in the right panel of Figure 1 , N 1 and N 0 units are assigned to treatments 1 and 0 respectively, where N 1 and N 0 are predetermined. From these two groups, n 1 and n 0 units are sampled and their responses are observed. Letȳ(1) andȳ(0) denote the observed averages for the treatment groups 1 and 0, respectively. Then, a natural estimator of τ iŝ
We will examine the sampling properties ofτ and compare them with those of a similar estimator τ obtained from Design 1 shown in Figure 1 .
Sampling properties of the estimator of ATE
Because the potential outcomes are assumed fixed, the sampling properties ofτ defined in (4) will be determined by the random variables associated with the randomization and sampling stages. We define two such variables now. For i = 1, . . . , N , let T i denote a Bernoulli random variable indicating the random level of treatment (0 or 1) that unit i receives. Recalling that the assignment mechanism essentially involves a random partitioning of N units into two groups of predetermined sizes N 0 and N 1 , the properties of the assignment vector (T 1 , . . . , T N ) are straightforward to establish and can be found in standard texts (e.g., Imbens and Rubin 2015) .
i as an indicator random variable equaling 1 if the potential outcome Y i (T i ) is randomly sampled among the units assigned to treatment level T i ∈ {0, 1}. Importantly, note that we know that S 1 i = 0 conditional on T i = 0; i.e., the ith unit will not be sampled from treatment group 1 if it was assigned to the treatment group 0. As shown in the right panel of Figure 1 , we assume that samples of size n 0 and n 1 are sampled from treatment groups 0 and 1, respectively. i can be summarized as:
Properties of the S
Var S
Cov S
Remark 1. To provide some intuition for (7), note that we expect the quantity Cov S
i is less likely to be sampled in the same group. Similarly, we expect the quantity Cov S 0 i , S 1 i to be positive, because if we know that unit i is sampled in treatment group 1, then unit i is more likely to be sampled in treatment group 0.
We now represent the estimatorτ in (4) in terms of the potential outcomes and the random variables T i and S T i i defined above. To do this, note that the average observed response in treatment group T ∈ {0, 1} can be written as
By combining (4) and (8) and using Lemma 1, we now derive the sampling properties of the estimatorτ and summarize them in Theorem 1. The proof of Theorem 1 is in Appendix B.
Theorem 1. The estimatorτ given by (4) satisfies the following properties:
1.τ is an unbiased estimator of the ATE τ .
2. The sampling variance ofτ is given by
where S 2 0 and S 2 1 are given by (1) and S 2 τ is given by (3).
Comparison with other designs
We now compare the sampling properties ofτ as derived in Theorem 1 with the unbiased estimators of τ obtained from two other designs: (i) a design where responses for all units are observed, that is, no sampling is involved, and (ii) a design described as Design 1 in the left panel of Figure 1 , where n units are first sampled from N units in the population and subsequently exposed to treatments.
We denote the estimator of τ from (i) by τ and that from (ii) by τ . Both τ and τ are unbiased estimators of τ . Neyman (1923) derived the following result on the sampling variance of τ :
The following expression for the sampling variance of τ was derived in Chapter 6 (Appendix B) of Imbens and Rubin (2015) :
Noting that
and consequently
we have
Comparing (9) to (10) and (12), we obtain the following inequality:
The first inequality in (13) reflects the price one has to pay for sampling from the finite population. The second inequality reflects the advantage of exposing all units to the treatments rather than a sample. Thus, if practical considerations permit Design 2 in Figure 1 , then it may be preferable to Design 1. Of course, under strict additivity of treatment effects, that is, τ i = τ for all i = 1, . . . , N , the last terms in (9) and (12) vanish and Designs 1 and 2 become equivalent in terms of the sampling variance of the estimator of τ .
Estimation of sampling variance and approximate confidence intervals
Let
denote the sample variances of observed responses for treatment groups 0 and 1, respectively. From standard sampling theory (e.g., Lohr 2009, Pages 52-54), it follows that s 2 0 and s 2 1 are unbiased estimators of S 2 0 and S 2 1 , respectively. Consequently,
is a natural Neymanian-style estimator of Var(τ ), which, as noted and discussed by several authors, has an upward bias of S 2 τ /N unless strict additivity holds. The estimator of Var( τ ) in Design 1
of Figure 1 will be essentially the same as (15), but will have a smaller upward bias of S 2 τ /N 2 .
Both estimators will be unbiased under strict additivity. Estimator (15) can be used to obtain approximate confidence intervals for τ aŝ
where Φ −1 (·) denotes the quantile function of a standard normal distribution. The asymptotic normality ofτ is based on the finite population central limit theorem (Hájek 1960) and its application in the context of randomized experiments by Li and Ding (2017) .
4. Can the estimator be improved using pre-treatment measurements?
Now assume that the response can be measured for each experimental unit prior to application of the treatments. Let X 1 , . . . , X N denote these measurements for the N units, which are fixed quantities like the potential outcomes. The unit-level differences
. . , N are referred to as "gain scores" in the psychology (Rumrill and Bellini 2017) and education (McGowen and Davis 2002) literature. While the unit-level gain scores or their
are of interest in psychology and education (Hake 1998), they are not referred to as causal estimands or causal effects (Rubin et al. 2004; Imbens and Rubin 2015) . However, it is easy to see that the unit-level and average treatment effects can respectively be expressed as the unit-level and average differences of the gain scores, i.e., τ i = ∆ 1i − ∆ 0i and τ = ∆ 1 − ∆ 0 . In spite of this connection, several experts in education and psychology have recommended avoiding the use of gain scores when estimating treatment effects in experiments and observational studies. Campbell and Erlebacher (1970) claimed, "gain scores are in general . . . a treacherous quicksand," and Cronbach and Furby (1970) recommended researchers to "frame their questions in other ways." Despite some recent interest on utilizing gain scores to identify causal effects, there appears to be a general aversion in the causal inference community towards the use of gain scores. Here we explore whether, in the current setup, a proper design and analysis of the experiment using gain scores can potentially lead to more precise estimation of treatment effects under certain assumptions.
In the setup of Design 2 in Figure 1 , where measuring the pre-treatment response for each unit is not feasible, it is often a common practice to measure the pre-treatment response for a random sample of size n x to estimate the average gain scores ∆ 1 and ∆ 0 . Denoting the sampling indicator by Z 1 , . . . , Z N , the estimators of ∆ 1 and ∆ 0 areȳ(1) −x andȳ(0) −x, respectively, wherē
While the sampling properties of these estimators can be readily obtained, they do not help in increasing the precision of the estimator ofτ because the average pre-treatment scores get canceled out in the difference of the gain score estimators. However, if samples of n x 1
and n x 0 pre-treatment observations are taken independently from the treatment groups 1 and 0 after assignment but before administration of the treatments, it is possible to obtain a different estimator of the ATE. For i = 1, . . . , N , let Z T i i denote the sampling indicator associated with the random sampling of X i among the units assigned to treatment T i . Then
are the observed sample averages of pre-treatment responses for the two treatment groups. Then we can define the following estimator of the ATE:
wherex ( is given by:
The proof for Lemma 3 is in Appendix C. Using Lemmas 2 and 3, we arrive at the following result:
Theorem 2. The estimatorτ * given by (17) satisfies the following properties:
1.τ * is an unbiased estimator of the ATE τ .
2. The sampling variance ofτ * is given by
where Var(τ ) is given by (9) and
The proof of Theorem 2 is in Appendix D.
Remark 2. From Theorem 2, it follows thatτ * is a more efficient estimator thanτ if and only if
where r T x = S T x S T Sx denotes the finite sample correlation coefficient between the potential outcomes Y (T ) and pre-treatment measurements X. In order for condition (21) to be achieved, pre-treatment measurements need to be highly predictive of the outcome, post-treatment outcomes need to be substantially variable relative to the pre-treatment measurements, and pre-treatment measurements need to be obtained for a large portion of the population. For example, consider the case where we have a balanced design (i.e., N 1 = N 0 = N/2) and a balanced sample size (n x 1 = n x 0 = n x /2). In this case, even if the pre-treatment measurements are perfectly correlated with the outcomes (i.e., r 1x = r 0x = 1), in order for (21) to be achieved, we need nx N (S 1 + S 0 ) > S x , and usually nx N will be small due to resource constraints. Similarly, if the pre-treatment measurements are moderately correlated with the outcomes (e.g., r 1x = r 0x = 0.5) and all units' pre-treatment measurements are observed (i.e., n x = N ), we still need
> S x , i.e., the average standard deviation of the post-treatment outcomes needs to be larger than the standard deviation of the pre-treatment measurements. Cases where r 1x = r 0x = 1 or n x = N are indeed quite extreme and unrealistic conditions, and thus Theorem 2 in general gives credence to the skepticism many causal inference experts have about using gain scores for estimation of treatment effects in the context of the experimental design discussed here.
Discussion
Many causal inference works have focused on experimental settings where the outcomes for all units in the experiment can be measured. In some settings, it is too expensive to conduct an experiment on all units of interest, and instead an experiment is conducted on a random sample of units. Texts such as Imbens and Rubin (2015) have shown that the inferential properties of common treatment effect estimators in these settings can be established by first accounting for the stochasticity of the sampling stage and then accounting for the stochasticity of the randomization stage. However, inferential properties under the experimental design scenario where the ordering of the sampling and randomization stages are reversed has not been established. Forms of this experimental design have become increasingly common in the physical, medical, and social sciences, and so it is important to understand statistical inference in this case.
We established the inferential properties of the mean-difference estimator under this experimental design scenario, and we compared our findings to results for other experimental designs.
Notably, the mean-difference estimator is more precise when treatment is randomized before units are sampled, as compared to the sample-first-randomize-second design, which is the more common experimental design discussed in the literature. However, this is only the case when there is treatment effect heterogeneity among units in the population of interest. We also assessed if pre-treatment measurements of units' outcomes can be used to improve upon the mean-difference estimator for this experimental design scenario. We found that this is only the case if (1) the pretreatment measurements are highly predictive of the outcome, (2) the post-treatment outcomes are substantially variable relative to the pre-treatment measurements, and (3) pre-treatment measurements are obtained for a large portion of the population.
A recent strand of causal inference literature has elucidated and leveraged the connection between experimental design and finite population sampling to refine theory and methodology for randomized experiments. This includes theory on design-based estimators for treatment effects (Samii and Aronow 2012; Aronow and Middleton 2013) , properties of covariate-adjustment in randomized experiments (Freedman 2008; Lin 2013; Miratrix et al. 2013) , and methods for estimating treatment effects in complex experimental settings such as cluster-randomized experiments (Middleton and Aronow 2015), experiments with interference (Aronow and Samii 2013) , and experiments with multiple treatments (Mukerjee et al. 2018 ). This work continues this trend of using experimental design and finite population sampling techniques to characterize treatment effect estimation in randomized experiments, particularly when the ordering of the randomization and sampling stages of the experiment are consequential for treatment effect estimation. A promising line for future work is to investigate other types of experiments where there are multiple stages of stochasticity and assess when the ordering of these stages is consequential to the analysis, and when measurements before and between stages of the experiment can be used to improve inference.
Appendix Appendix A: Proof of Lemma 1
To prove (5), note that E S
Next, we have that Var S
which proves (6).
To prove (7), first we consider the case where i = i and T i = T i :
Next, for the case where i = i and T i = T i , we have that:
= P r Units i, i both receive treatment T i and are sampled = P r i, i are both sampled | both receive T i P r [both receive
Thus, it follows that, Cov S
after a little algebra.
Finally, for the case where i = i and T i = T i , we have that: 
.
Appendix B: Proof of Theorem 1
To prove the first part, note that for T ∈ {0, 1},ȳ(T ) defined in (8) is an unbiased estimator of Y (T ) by (5). Consequently, from (4),τ is an unbiased estimator of τ . To prove the second part, we need the following three lemmas:
Lemma 4. For T ∈ {0, 1},
Proof. By (1), for T ∈ {0, 1},
Lemma 5. For T ∈ {0, 1},
Proof. By (8), for T ∈ {0, 1},
Lemma 6. The covariance betweenȳ (1) andȳ (0) is given by:
Proof.
The result follows from the identity S 10 = S 2 1 + S 2 0 − S 2 τ /2, which is straightforward to establish.
Straightforward applications of Lemma 5 and Lemma 6 lead to the proof of Theorem 1.
Appendix C: Proof of Lemma 3
We will consider the four cases in Lemma 3. For the first case, when i = i and
Now for the second case. When i = i and T i = T i , P r(S
Plugging this into the same procedure as (22), we have that Cov(S
Now for the third case. When i = i and
Now for the fourth case. When i = i and
, after some algebra.
Appendix D: Proof of Theorem 2
To prove this theorem, we first state and prove the following two lemmas:
Lemma 7 
where the last step follows by substitution of the relevant expressions from Lemma 8.
Finally, the result follows by substituting (27) and (28) in (26).
